Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23620946 | 0.90 | GPR119 (0.50) | GPR119CHRNA7 | |
| SCHEMBL20502297 | 0.90 | GPR119 (0.50) | GPR119CHRNA7 | |
| SCHEMBL30307823 | 0.90 | GPR119 (0.50) | GPR119CHRNA7 | |
| SCHEMBL23620970 | 0.79 | CA2 (0.47) | GPR119USP30 | |
| SCHEMBL23620947 | 0.79 | CA2 (0.48) | GPR119CHRNA7USP30 | |
| SCHEMBL20502304 | 0.79 | GPR119 (0.54) | GPR119 | |
| SCHEMBL23620950 | 0.79 | GPR119 (0.54) | GPR119 | |
| SCHEMBL23620982 | 0.76 | GPR119 (0.52) | GPR119CHRNA7 | |
| SCHEMBL23620959 | 0.74 | CA1 (0.39) | EPHX2NR1H4 | |
| SCHEMBL20502327 | 0.74 | CA1 (0.39) | EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596059-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | GPR119 3054/4885HSD11B1 4701/4885CHRNA7 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.